HYTERA
24.5.2021 12:24:07 CEST | Business Wire | Press release
Hytera , as a world leading provider of professional communications technologies and solutions, brings body worn cameras (BWC) to a new level with innovative hardware and software design, convergence with push-to-talk technology, and integration with control room solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005363/en/
Hytera has full series of 4G or LTE body worn cameras which can capture HD video to provide evidence for trials. More importantly, they are able to send live video back to the control center over 4G network. This helps the dispatcher know exactly what is happening, enhance real-time situational awareness and facilitate decision-making. Hytera has launched a comprehensive solution including the body worn camera, integrated device station and digital evidence management platform.
Designed for the field with evidence management in mind, the VM780 takes RVM Bodycams to the next level with the most advanced range of features available, including a 2.8” touch display, 3G/ 4G & Wi-Fi for real time transmission anywhere, GPS built-in and Push-to-talk over cellular (PoC) application compatibility. The device features a 216° rotatable camera and powerful 3-watt speaker to deliver loud and clear audio during the call, even in highly noisy environments. It also supports NFC and Bluetooth connectivity, AES256 advanced encryption technology, and simple charging and programming via the micro-USB interface.
The VM580D is suitable for both mission critical and commercial users. It’s slim (only 20mm thick), lightweight and easy to operate with one hand for photo taking, audio and video recording. It can share real-time GPS location information over LTE, 3G, and Wi-Fi networks. The device also serves as a PoC radio, which can be used for evidence collection simultaneously with a PoC platform such as Hytera HyTalk.
Hytera also provides various related software and hardware including storage, evidence collection, evidence classification, and dispatch platform, etc. Hytera is one of the few companies which can provide E2E body worn cameras solution to customers.
It's known to all that it is not uncommon for the officers to face the confrontations or dispute from the public during onsite law enforcement. Public safety and governmental institutions have increasingly advocated or legislated the use of BWC for promoting law enforcement transparency, deterring the violence and increasing trial efficiency. For example, a Dubai ruler issued a resolution to authorize its police to use security cameras in public areas to fulfill its duties including handling traffic violations and ensuring effective security. Hytera BWC Solution has been adopted by government and industry customers including the Shanghai Police and Macau Police to restore the truth of what happened with the first-person recording, voice and video, and bring better transparency and accountability to help improve law enforcement legitimacy.
Learn more at http://www.hytera.ae .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005363/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom